Different actions for acute and chronic administration of mirtazapine on serotonergic transmission associated with raphe nuclei and their innervation cortical regions

Neuropharmacology

Volumn 60, Issue 4, 2011, Pages 550-560

  Yamamura, Satoshi ^a   Abe, Masao ^b   Nakagawa, Masanori ^a   Ochi, Shinichiro ^b   Ueno, Shu Ichi ^b   Okada, Motohiro ^a  

^a MIE UNIVERSITY   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cortex; Microdialysis; Mirtazapine; Raphe nuclei; Serotonin

Indexed keywords

MESSENGER RNA; MIRTAZAPINE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENTORHINAL CORTEX; EXTRACELLULAR SPACE; FRONTAL CORTEX; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAPHE NUCLEUS; RAT; SEROTONIN BRAIN LEVEL; SEROTONINERGIC TRANSMISSION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BLOTTING, WESTERN; CEREBRAL CORTEX; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; INFUSION PUMPS; MALE; MIANSERIN; NEURONS; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 79251599505     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.12.025     Document Type: Article

References (42)

1. A. Adell, P. Celada, M.T. Abellan, and F. Artigas Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei Brain Res. Brain Res. Rev. 39 2002 154 180
2. S.P. Alexander, A. Mathie, and J.A. Peters Guide to Receptors and Channels (GRAC), fourth ed Br. J. Pharmacol. 158 Suppl. 1 2009 S1 S254
3. N.M. Barnes, and T. Sharp A review of central 5-HT receptors and their function Neuropharmacology 38 1999 1083 1152
4. H.J. Bengtsson, J. Kele, J. Johansson, and S. Hjorth Interaction of the antidepressant mirtazapine with alpha2-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo Naunyn Schmiedebergs Arch. Pharmacol. 362 2000 406 412
5. S. Benmansour, W.A. Owens, M. Cecchi, D.A. Morilak, and A. Frazer Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter J. Neurosci. 22 2002 6766 6772
6. A. Besson, N. Haddjeri, P. Blier, and C. de Montigny Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain Eur. Neuropsychopharmacol. 10 2000 177 188
7. N.S. Bhide, J.W. Lipton, J.I. Cunningham, B.K. Yamamoto, and G.A. Gudelsky Repeated exposure to MDMA provides neuroprotection against subsequent MDMA-induced serotonin depletion in brain Brain Res. 1286 2009 32 41
8. J.M. Casanovas, I. Hervas, and F. Artigas Postsynaptic 5-HT1A receptors control 5-HT release in the rat medial prefrontal cortex Neuroreport 10 1999 1441 1445
9. Y. Chaput, C. de Montigny, and P. Blier Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat Neuropsychopharmacology 5 1991 219 229
10. A. Cipriani, T.A. Furukawa, G. Salanti, J.R. Geddes, J.P. Higgins, R. Churchill, N. Watanabe, A. Nakagawa, I.M. Omori, H. McGuire, M. Tansella, and C. Barbui Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis Lancet 373 2009 746 758
11. K.F. Croom, C.M. Perry, and G.L. Plosker Mirtazapine: a review of its use in major depression and other psychiatric disorders CNS Drugs 23 2009 427 452
12. T.H. de Boer, F. Nefkens, A. van Helvoirt, and A.M. van Delft Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan J. Pharmacol. Exp. Ther. 277 1996 852 860
13. T. de Boer The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission Int. Clin. Psychopharmacol. 10 Suppl. 4 1995 19 23
14. T. de Boer The pharmacologic profile of mirtazapine J. Clin. Psychiatry 57 Suppl. 4 1996 19 25
15. P. Devoto, G. Flore, L. Pira, G. Longu, and G.L. Gessa Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex Eur. J. Pharmacol. 487 2004 105 111
16. J. Glowinski, and L.L. Iversen Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain J. Neurochem. 13 1966 655 669
17. N. Haddjeri, P. Blier, and C. de Montigny Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain J. Pharmacol. Exp. Ther. 277 1996 861 871
18. H. Imai, D.A. Steindler, and S.T. Kitai The organization of divergent axonal projections from the midbrain raphe nuclei in the rat J. Comp. Neurol. 243 1986 363 380
19. B.L. Jacobs, and E.C. Azmitia Structure and function of the brain serotonin system Physiol. Rev. 72 1992 165 229
20. D.S. Kreiss, and I. Lucki Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo J. Pharmacol. Exp. Ther. 274 1995 866 876
21. F. Lechin, B. van der Dijs, J. Amat, and M.E. Lechin Neuroanatomical basis F. Lechin, B. van der Dijs, Neurochemistry and Clinical Disorders:circuitry of Some Psychiatric and Psychosomatic Syndromes 1989 CRC Press Boca Raton 9 12
22. F. Lechin, B. van der Dijs, and M.E. Lechin Neuroautonomic, neuroendocrine and neuroimmune interactions F. Lechin, B. van der Dijs, M.E. Lechin, Neurocircuitry and Neuroautonomic Disorders Reviews and Therapeutic Strategies 2002 karger Basel 57 59
23. F. Lechin, B. van der Dijs, and G. Hernandez-Adrian Dorsal raphe vs. median raphe serotonergic antagonism. Anatomical, physiological, behavioral, neuroendocrinological, neuropharmacological and clinical evidences: relevance for neuropharmacological therapy Prog. Neuropsychopharmacol. Biol. Psychiatry 30 2006 565 585
24. Q. Li, N.A. Muma, and L.D. van de Kar Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist J. Pharmacol. Exp. Ther. 279 1996 1035 1042
25. Q. Li, N.A. Muma, G. Battaglia, and L.D. Van de Kar A desensitization of hypothalamic 5-HT1A receptors by repeated injections of paroxetine: reduction in the levels of G(i) and G(o) proteins and neuroendocrine responses, but not in the density of 5-HT1A receptors J. Pharmacol. Exp. Ther. 282 1997 1581 1590
26. C. McGrath, G.D. Burrows, and T.R. Norman Neurochemical effects of the enantiomers of mirtazapine in normal rats Eur. J. Pharmacol. 356 1998 121 126
27. H.Y. Meltzer, Z. Li, Y. Kaneda, and J. Ichikawa Serotonin receptors: their key role in drugs to treat schizophrenia Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 1159 1172
28. M.J. Millan, A. Gobert, J.M. Rivet, A. Adhumeau-Auclair, D. Cussac, A. Newman-Tancredi, A. Dekeyne, J.P. Nicolas, and F. Lejeune Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram Eur. J. Neurosci. 12 2000 1079 1095
29. K. Nakayama, T. Sakurai, and H. Katsu Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation Brain Res. Bull. 63 2004 237 241
30. Ohoyama, K., Yamamura, S., Hamaguchi, T., Nakagawa, M., Motomura, E., Shiroyama, T., Tanii, H., Okada, M., Effects of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur. J. Pharmacol., in press.
31. G. Paxinos, and C. Watson The Rat Brain: in Stereotoxic Coordinates 1998 Academic Press San Dieg
32. A. Pazos, and J.M. Palacios Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors Brain Res. 346 1985 205 230
33. M. Pfaffl Relative quantification T. Dorak, Real Time PCR (BIOS Advanced Methods) 2006 Taylor & Francis New York 63 82
34. D. Popa, J. Cerdan, C. Reperant, B.P. Guiard, J.P. Guilloux, D.J. David, and A.M. Gardier A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain Eur. J. Pharmacol. 628 2010 83 90
35. D.K. Raap, S. Evans, F. Garcia, Q. Li, N.A. Muma, W.A. Wolf, G. Battaglia, and L.D. Van De Kar Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins J. Pharmacol. Exp. Ther. 288 1999 98 106
36. M. Suzuki, T. Matsuda, S. Asano, P. Somboonthum, K. Takuma, and A. Baba Increase of noradrenaline release in the hypothalamus of freely moving rat by postsynaptic 5-hydroxytryptamine1A receptor activation Br. J. Pharmacol. 115 1995 703 711
37. M. Tatsumi, K. Groshan, R.D. Blakely, and E. Richelson Pharmacological profile of antidepressants and related compounds at human monoamine transporters Eur. J. Pharmacol. 340 1997 249 258
38. M. Van der Mey, A.D. Windhorst, R.P. Klok, J.D. Herscheid, L.E. Kennis, F. Bischoff, M. Bakker, X. Langlois, L. Heylen, M. Jurzak, and J.E. Leysen Synthesis and biodistribution of [11C]R107474, a new radiolabeled alpha2-adrenoceptor antagonist Bioorg. Med. Chem. 14 2006 4526 4534
39. C.H. West, J.C. Ritchie, K.A. Boss-Williams, and J.M. Weiss Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons Int. J. Neuropsychopharmacol 12 2009 627 641
40. S. Yamamura, K. Ohoyama, T. Hamaguchi, M. Nakagawa, D. Suzuki, T. Matsumoto, E. Motomura, H. Tanii, T. Shiroyama, and M. Okada Effects of zotepine on extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex Br. J. Pharmacol. 157 2009 656 665
41. S. Yamamura, K. Ohoyama, H. Nagase, and M. Okada Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway Neuropharmacology 57 2009 322 331
42. G. Zhu, M. Okada, S. Yoshida, S. Ueno, F. Mori, T. Takahara, R. Saito, Y. Miura, A. Kishi, M. Tomiyama, A. Sato, T. Kojima, G. Fukuma, K. Wakabayashi, K. Hase, H. Ohno, H. Kijima, Y. Takano, A. Mitsudome, S. Kaneko, and S. Hirose Rats harboring S284L Chrna4 mutation show attenuation of synaptic and extrasynaptic GABAergic transmission and exhibit the nocturnal frontal lobe epilepsy phenotype J. Neurosci. 28 2008 12465 12476